Ignite Creation Date:
2025-12-24 @ 11:54 PM
Ignite Modification Date:
2026-01-24 @ 5:09 AM
Study NCT ID:
NCT02881151
Status:
COMPLETED
Last Update Posted:
2022-12-23
First Post:
2016-08-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Deep Brain Stimulation for the Treatment of Traumatic Brain Injury
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2022-11-10', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D000070642', 'term': 'Brain Injuries, Traumatic'}], 'ancestors': [{'id': 'D001930', 'term': 'Brain Injuries'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D006259', 'term': 'Craniocerebral Trauma'}, {'id': 'D020196', 'term': 'Trauma, Nervous System'}, {'id': 'D014947', 'term': 'Wounds and Injuries'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D046690', 'term': 'Deep Brain Stimulation'}], 'ancestors': [{'id': 'D004599', 'term': 'Electric Stimulation Therapy'}, {'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D013514', 'term': 'Surgical Procedures, Operative'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'henderj@stanford.edu', 'phone': '+1 (650) 723-5574', 'title': 'Dr. Jaimie Henderson', 'organization': 'Stanford University School of Medicine'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': '1 year (treatment phase plus continuation phase)', 'description': 'Adverse events are presented in a single group because the study was designed to assess any adverse events during the study as a whole, not whether adverse events were associated with any particular study phase.', 'eventGroups': [{'id': 'EG000', 'title': 'Treatment', 'description': 'Subjects will be treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that will be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 4, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 2}], 'otherEvents': [{'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Wound site bleeding', 'notes': 'Scabbing at surgical site with small amount of bleeding', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Unintended stimulator deactivation', 'notes': 'Stimulator de-activated unintentionally (felt to be due to theft detector in store)', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Product Issues', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Gait disturbance', 'notes': 'Gait unsteadiness (self limited)', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Neck pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Lower extremity pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Tinnitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Cognitive difficulty', 'notes': 'Difficulty with planning, organization and word recall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'COVID-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'seriousEvents': [{'term': 'Infection of DBS device', 'notes': 'Infection of deep brain stimulator system, requiring removal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Syncope', 'notes': 'Syncope when standing to urinate', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percent Change in Trail Making Test Part B Time to Completion', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment', 'description': 'Subjects were treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that was be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.'}], 'classes': [{'categories': [{'measurements': [{'value': '-25.6', 'groupId': 'OG000', 'lowerLimit': '-42.26', 'upperLimit': '-23.94'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Trail Making Test is a measure of attention, speed and mental flexibility. It also tests spatial organization, visual pursuits, recall, and recognition. Part A requires the individual to draw lines to connect 25 encircled numbers distributed on a page. Part A tests visual scanning, numeric sequencing, and visuomotor speed. Part B is similar except the person must alternate between numbers and letters and is believed to be more difficult and takes longer to complete. Part B tests cognitive demands including visual motor and visual spatial abilities and mental flexibility. Both sections are timed and the score represents the amount of time required to complete the task. Lower scores (shorter times) correspond to a better outcome.', 'unitOfMeasure': 'percent change in time', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Subjects who completed all study assessments through the open label treatment phase'}, {'type': 'SECONDARY', 'title': 'Percent Change in Trail Making Test Part A Time to Completion', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment', 'description': 'Subjects were treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that was be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.'}], 'classes': [{'categories': [{'measurements': [{'value': '-27.4', 'groupId': 'OG000', 'lowerLimit': '-33.06', 'upperLimit': '-25.34'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Trail Making Test is a measure of attention, speed and mental flexibility. It also tests spatial organization, visual pursuits, recall, and recognition. Part A requires the individual to draw lines to connect 25 encircled numbers distributed on a page. Part A tests visual scanning, numeric sequencing, and visuomotor speed. Part B is similar except the person must alternate between numbers and letters and is believed to be more difficult and takes longer to complete. Part B tests cognitive demands including visual motor and visual spatial abilities and mental flexibility. Both sections are timed and the score represents the amount of time required to complete the task. Lower scores (shorter times) correspond to a better outcome.', 'unitOfMeasure': 'percent change in time', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Subjects who completed all study assessments through the open label treatment phase'}, {'type': 'SECONDARY', 'title': 'Percent Change in Traumatic Brain Injury Quality of Life - Executive Function Short Form (TBI-QOL) Scale Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment', 'description': 'Subjects were treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that was be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.'}], 'classes': [{'categories': [{'measurements': [{'value': '28.0', 'groupId': 'OG000', 'lowerLimit': '19.44', 'upperLimit': '53.57'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The TBI-QOL was developed as a comprehensive patient-reported outcomes (PRO) measurement system specifically for individuals with TBI. It consists of 20 independent calibrated item banks and 2 uncalibrated scales that measure physical, emotional, cognitive, and social aspects of health-related quality of life. We will administer the short form (6-10 questions each) of the TBI-QOL Fatigue, Attention/Concentration, and Executive Function subscales. Executive Function score range: 10-50, higher scores correspond to better executive function.', 'unitOfMeasure': 'percent change in score', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Subjects who completed all study assessments through the open label treatment phase'}, {'type': 'SECONDARY', 'title': 'Percent Change Traumatic Brain Injury Quality of Life - Attention/Concentration Short Form Scale Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment', 'description': 'Subjects were treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that was be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.'}], 'classes': [{'categories': [{'measurements': [{'value': '66.7', 'groupId': 'OG000', 'lowerLimit': '57.85', 'upperLimit': '92.86'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The TBI-QOL was developed as a comprehensive patient-reported outcomes (PRO) measurement system specifically for individuals with TBI. It consists of 20 independent calibrated item banks and 2 uncalibrated scales that measure physical, emotional, cognitive, and social aspects of health-related quality of life. We will administer the short form (6-10 questions each) of the TBI-QOL Fatigue, Attention/Concentration, and Executive Function subscales. Attention/Concentration score range: 6-30, higher scores correspond to better attention and concentration.', 'unitOfMeasure': 'percent change in score', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Subjects who completed all study assessments through the open label treatment phase'}, {'type': 'SECONDARY', 'title': 'Percent Change in Traumatic Brain Injury Quality of Life - Fatigue Short Form Scale Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment', 'description': 'Subjects were treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that was be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.9', 'groupId': 'OG000', 'lowerLimit': '-20.00', 'upperLimit': '5.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The TBI-QOL was developed as a comprehensive patient-reported outcomes (PRO) measurement system specifically for individuals with TBI. It consists of 20 independent calibrated item banks and 2 uncalibrated scales that measure physical, emotional, cognitive, and social aspects of health-related quality of life. We will administer the short form (6-10 questions each) of the TBI-QOL Fatigue, Attention/Concentration, and Executive Function subscales. Fatigue score range: 10-50, lower scores correspond to less fatigue.', 'unitOfMeasure': 'percent change in score', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Subjects who completed all study assessments through the open label treatment phase'}, {'type': 'SECONDARY', 'title': 'Percent Change in Rivermead Post-Concussion Symptom Questionnaire Scale Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment', 'description': 'Subjects were treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that was be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.'}], 'classes': [{'categories': [{'measurements': [{'value': '-36.6', 'groupId': 'OG000', 'lowerLimit': '-62.16', 'upperLimit': '-6.25'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Rivermead PCS Questionnaire (RPQ) was originally developed as a measure of severity of symptoms following mild TBI. It consists of 16 post-concussion symptoms including headaches, dizziness, nausea/vomiting, noise sensitivity, sleep disturbance, fatigue, irritability, feeling depressed/tearful, feeling frustrated/ impatient, forgetfulness, poor concentration, taking longer to think, blurred vision, light sensitivity, double vision and restlessness. In the original version of the RPQ, participants are asked to rate the degree (on a scale of 0 to 4) to which a particular symptom has been absent or a mild, moderate or severe problem over the previous 24 hours compared with premorbid levels. Score range: 0-64, lower scores correspond to fewer symptoms', 'unitOfMeasure': 'percent change in score', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Subjects who completed all study assessments through the open label treatment phase'}, {'type': 'SECONDARY', 'title': 'Percent Change in Ruff 2 and 7 Automatic Detection Speed Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment', 'description': 'Subjects were treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that was be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.'}], 'classes': [{'categories': [{'measurements': [{'value': '21.1', 'groupId': 'OG000', 'lowerLimit': '3.87', 'upperLimit': '23.17'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Ruff 2 \\& 7 Test was developed to measure two aspects of visual attention: sustained attention (ability to maintain consistent performance level over time) and selective attention (ability to select relevant stimuli while ignoring distractors). The test consists of a series of 20 trials of a visual search and cancellation task. The respondent detects and marks through all occurrences of the two target digits: "2" and "7." In the 10 Automatic Detection trials, the target digits are embedded among alphabetical letters that serve as distractors. In the 10 Controlled Search trials, the target digits are embedded among other numbers that serve as distractors. Correct hits and errors are counted for each trial and serve as the basis for scoring the test. Speed scores reflect the total number of correctly identified targets (hits). Score range: 0 to 300, with higher numbers representing more correctly identified targets within the allotted time (5 minutes)', 'unitOfMeasure': 'percent change in score', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Subjects who completed all study assessments through the open label treatment phase'}, {'type': 'SECONDARY', 'title': 'Percent Change in Ruff 2 and 7 Automatic Detection Accuracy Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment', 'description': 'Subjects were treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that was be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.2', 'groupId': 'OG000', 'lowerLimit': '1.83', 'upperLimit': '7.94'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Ruff 2 \\& 7 Test was developed to measure two aspects of visual attention: sustained attention (ability to maintain consistent performance level over time) and selective attention (ability to select relevant stimuli while ignoring distractors). The test consists of a series of 20 trials of a visual search and cancellation task. The respondent detects and marks through all occurrences of the two target digits: "2" and "7." In the 10 Automatic Detection trials, the target digits are embedded among alphabetical letters that serve as distractors. In the 10 Controlled Search trials, the target digits are embedded among other numbers that serve as distractors. Correct hits and errors are counted for each trial and serve as the basis for scoring the test. Accuracy scores evaluate the number of targets identified in relation to the number of possible targets (n=300), expressed as a percentage. Higher scores represent higher accuracy of target identification.', 'unitOfMeasure': 'percent change in score', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Subjects who completed all study assessments through the open label treatment phase'}, {'type': 'SECONDARY', 'title': 'Percent Change in Ruff 2 and 7 Controlled Search Speed Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment', 'description': 'Subjects were treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that was be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.'}], 'classes': [{'categories': [{'measurements': [{'value': '17.3', 'groupId': 'OG000', 'lowerLimit': '14.47', 'upperLimit': '25.39'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Ruff 2 \\& 7 Test was developed to measure two aspects of visual attention: sustained attention (ability to maintain consistent performance level over time) and selective attention (ability to select relevant stimuli while ignoring distractors). The test consists of a series of 20 trials of a visual search and cancellation task. The respondent detects and marks through all occurrences of the two target digits: "2" and "7." In the 10 Automatic Detection trials, the target digits are embedded among alphabetical letters that serve as distractors. In the 10 Controlled Search trials, the target digits are embedded among other numbers that serve as distractors. Correct hits and errors are counted for each trial and serve as the basis for scoring the test. Speed scores reflect the total number of correctly identified targets (hits). Score range: 0 to 300, with higher numbers representing more correctly identified targets within the allotted time (5 minutes)', 'unitOfMeasure': 'percent change in score', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Subjects who completed all study assessments through the open label treatment phase, and who had calculable scores'}, {'type': 'SECONDARY', 'title': 'Percent Change in Ruff 2 and 7 Controlled Search Accuracy Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment', 'description': 'Subjects were treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that was be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.7', 'groupId': 'OG000', 'lowerLimit': '1.29', 'upperLimit': '5.03'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Ruff 2 \\& 7 Test was developed to measure two aspects of visual attention: sustained attention (ability to maintain consistent performance level over time) and selective attention (ability to select relevant stimuli while ignoring distractors). The test consists of a series of 20 trials of a visual search and cancellation task. The respondent detects and marks through all occurrences of the two target digits: "2" and "7." In the 10 Automatic Detection trials, the target digits are embedded among alphabetical letters that serve as distractors. In the 10 Controlled Search trials, the target digits are embedded among other numbers that serve as distractors. Correct hits and errors are counted for each trial and serve as the basis for scoring the test. Accuracy scores evaluate the number of targets identified in relation to the number of possible targets (n=300), expressed as a percentage. Higher scores represent higher accuracy of target identification.', 'unitOfMeasure': 'percent change in score', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Subjects who completed all study assessments through the open label treatment phase, and who had calculable scores'}, {'type': 'SECONDARY', 'title': 'Percent Change in Patient Health Questionnaire - 9 Scale Score.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment', 'description': 'Subjects were treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that was be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.'}], 'classes': [{'categories': [{'measurements': [{'value': '-41.7', 'groupId': 'OG000', 'lowerLimit': '-80.00', 'upperLimit': '-30.77'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Participant Health Questionnaire 9 is a standardized assessment instrument designed to screen, diagnose, monitor, and measure the severity of depression. Score range: 0 to 27, lower scores correspond to better health outcomes.', 'unitOfMeasure': 'percent change in score', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Subjects who completed all study assessments through the open label treatment phase'}, {'type': 'SECONDARY', 'title': 'Number of Participants With ≥1 Point Increase in Glasgow Outcome Scale - Extended Scale Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment', 'description': 'Subjects will be treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that will be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.'}], 'classes': [{'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Glasgow Outcome Scale Extended (GOS-E) is a measure of disability and handicap intended for use following head injury. The GOS-E subdivides the upper three categories of the original Glasgow Outcome Scale (GOS), severe disability, moderate disability and good recovery, into an eight-category scale: 1 = dead, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery to provide more detailed assessment of the functional effects of the injury. A structured interview has been developed to standardize assignment of an outcome category (Wilson et al. 1998). Increase of 1 point on this scale represents a meaningful change in health outcome.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Subjects who completed all study assessments through the open label treatment phase'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Treatment', 'description': 'Subjects were treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that was be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.'}], 'periods': [{'title': 'Hospital Admission and Surgery (3 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}]}, {'title': 'Post-surgical Washout (65 to 93 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Device explantation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}]}]}, {'title': 'DBS Titration-Optimization (14 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}]}, {'title': 'Unblinded Treatment Phase (90 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}]}, {'title': 'Withdrawal Phase (21 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'comment': '2 participants did not participate in the Withdrawal Phase (declined stimulator deactivation) but did proceed to the Continuation Phase.', 'groupId': 'FG000', 'numSubjects': '3'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}]}, {'title': 'Continuation Phase (6 Months)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Treatment', 'description': 'Subjects were treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that was be undertaken to assess for any possible therapeutic effect.\n\nDeep brain stimulation: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '34', 'groupId': 'BG000', 'lowerLimit': '22', 'upperLimit': '60'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '2', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '4', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '6', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'White', 'measurements': [{'value': '6', 'groupId': 'BG000'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '6', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Years since injury', 'classes': [{'categories': [{'measurements': [{'value': '6.5', 'groupId': 'BG000', 'lowerLimit': '3.25', 'upperLimit': '9.75'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'years', 'dispersionType': 'INTER_QUARTILE_RANGE'}, {'title': 'Years of education', 'classes': [{'categories': [{'measurements': [{'value': '14', 'groupId': 'BG000', 'lowerLimit': '13.25', 'upperLimit': '14.00'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'years', 'dispersionType': 'INTER_QUARTILE_RANGE'}, {'title': 'Trail-making test, part B', 'classes': [{'categories': [{'measurements': [{'value': '116.9', 'groupId': 'BG000', 'lowerLimit': '52.15', 'upperLimit': '163.21'}]}]}], 'paramType': 'MEDIAN', 'description': 'This test requires the connection of circles marked by numbers and letters in alternating sequence and is considered a benchmark of executive function. The test score is the time required to complete the task in seconds.', 'unitOfMeasure': 'seconds', 'dispersionType': 'INTER_QUARTILE_RANGE'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2022-01-30', 'size': 1078903, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_001.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2022-10-11T13:41', 'hasProtocol': True}, {'date': '2022-05-03', 'size': 341653, 'label': 'Informed Consent Form', 'hasIcf': True, 'hasSap': False, 'filename': 'ICF_000.pdf', 'typeAbbrev': 'ICF', 'uploadDate': '2022-09-26T12:49', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 6}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-04-20', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-11', 'completionDateStruct': {'date': '2022-05-04', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-11-30', 'studyFirstSubmitDate': '2016-08-22', 'resultsFirstSubmitDate': '2022-10-13', 'studyFirstSubmitQcDate': '2016-08-22', 'lastUpdatePostDateStruct': {'date': '2022-12-23', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2022-11-30', 'studyFirstPostDateStruct': {'date': '2016-08-26', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2022-12-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-10-13', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percent Change in Trail Making Test Part B Time to Completion', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Trail Making Test is a measure of attention, speed and mental flexibility. It also tests spatial organization, visual pursuits, recall, and recognition. Part A requires the individual to draw lines to connect 25 encircled numbers distributed on a page. Part A tests visual scanning, numeric sequencing, and visuomotor speed. Part B is similar except the person must alternate between numbers and letters and is believed to be more difficult and takes longer to complete. Part B tests cognitive demands including visual motor and visual spatial abilities and mental flexibility. Both sections are timed and the score represents the amount of time required to complete the task. Lower scores (shorter times) correspond to a better outcome.'}], 'secondaryOutcomes': [{'measure': 'Percent Change in Trail Making Test Part A Time to Completion', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Trail Making Test is a measure of attention, speed and mental flexibility. It also tests spatial organization, visual pursuits, recall, and recognition. Part A requires the individual to draw lines to connect 25 encircled numbers distributed on a page. Part A tests visual scanning, numeric sequencing, and visuomotor speed. Part B is similar except the person must alternate between numbers and letters and is believed to be more difficult and takes longer to complete. Part B tests cognitive demands including visual motor and visual spatial abilities and mental flexibility. Both sections are timed and the score represents the amount of time required to complete the task. Lower scores (shorter times) correspond to a better outcome.'}, {'measure': 'Percent Change in Traumatic Brain Injury Quality of Life - Executive Function Short Form (TBI-QOL) Scale Score', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The TBI-QOL was developed as a comprehensive patient-reported outcomes (PRO) measurement system specifically for individuals with TBI. It consists of 20 independent calibrated item banks and 2 uncalibrated scales that measure physical, emotional, cognitive, and social aspects of health-related quality of life. We will administer the short form (6-10 questions each) of the TBI-QOL Fatigue, Attention/Concentration, and Executive Function subscales. Executive Function score range: 10-50, higher scores correspond to better executive function.'}, {'measure': 'Percent Change Traumatic Brain Injury Quality of Life - Attention/Concentration Short Form Scale Score', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The TBI-QOL was developed as a comprehensive patient-reported outcomes (PRO) measurement system specifically for individuals with TBI. It consists of 20 independent calibrated item banks and 2 uncalibrated scales that measure physical, emotional, cognitive, and social aspects of health-related quality of life. We will administer the short form (6-10 questions each) of the TBI-QOL Fatigue, Attention/Concentration, and Executive Function subscales. Attention/Concentration score range: 6-30, higher scores correspond to better attention and concentration.'}, {'measure': 'Percent Change in Traumatic Brain Injury Quality of Life - Fatigue Short Form Scale Score', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The TBI-QOL was developed as a comprehensive patient-reported outcomes (PRO) measurement system specifically for individuals with TBI. It consists of 20 independent calibrated item banks and 2 uncalibrated scales that measure physical, emotional, cognitive, and social aspects of health-related quality of life. We will administer the short form (6-10 questions each) of the TBI-QOL Fatigue, Attention/Concentration, and Executive Function subscales. Fatigue score range: 10-50, lower scores correspond to less fatigue.'}, {'measure': 'Percent Change in Rivermead Post-Concussion Symptom Questionnaire Scale Score', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Rivermead PCS Questionnaire (RPQ) was originally developed as a measure of severity of symptoms following mild TBI. It consists of 16 post-concussion symptoms including headaches, dizziness, nausea/vomiting, noise sensitivity, sleep disturbance, fatigue, irritability, feeling depressed/tearful, feeling frustrated/ impatient, forgetfulness, poor concentration, taking longer to think, blurred vision, light sensitivity, double vision and restlessness. In the original version of the RPQ, participants are asked to rate the degree (on a scale of 0 to 4) to which a particular symptom has been absent or a mild, moderate or severe problem over the previous 24 hours compared with premorbid levels. Score range: 0-64, lower scores correspond to fewer symptoms'}, {'measure': 'Percent Change in Ruff 2 and 7 Automatic Detection Speed Score', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Ruff 2 \\& 7 Test was developed to measure two aspects of visual attention: sustained attention (ability to maintain consistent performance level over time) and selective attention (ability to select relevant stimuli while ignoring distractors). The test consists of a series of 20 trials of a visual search and cancellation task. The respondent detects and marks through all occurrences of the two target digits: "2" and "7." In the 10 Automatic Detection trials, the target digits are embedded among alphabetical letters that serve as distractors. In the 10 Controlled Search trials, the target digits are embedded among other numbers that serve as distractors. Correct hits and errors are counted for each trial and serve as the basis for scoring the test. Speed scores reflect the total number of correctly identified targets (hits). Score range: 0 to 300, with higher numbers representing more correctly identified targets within the allotted time (5 minutes)'}, {'measure': 'Percent Change in Ruff 2 and 7 Automatic Detection Accuracy Score', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Ruff 2 \\& 7 Test was developed to measure two aspects of visual attention: sustained attention (ability to maintain consistent performance level over time) and selective attention (ability to select relevant stimuli while ignoring distractors). The test consists of a series of 20 trials of a visual search and cancellation task. The respondent detects and marks through all occurrences of the two target digits: "2" and "7." In the 10 Automatic Detection trials, the target digits are embedded among alphabetical letters that serve as distractors. In the 10 Controlled Search trials, the target digits are embedded among other numbers that serve as distractors. Correct hits and errors are counted for each trial and serve as the basis for scoring the test. Accuracy scores evaluate the number of targets identified in relation to the number of possible targets (n=300), expressed as a percentage. Higher scores represent higher accuracy of target identification.'}, {'measure': 'Percent Change in Ruff 2 and 7 Controlled Search Speed Score', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Ruff 2 \\& 7 Test was developed to measure two aspects of visual attention: sustained attention (ability to maintain consistent performance level over time) and selective attention (ability to select relevant stimuli while ignoring distractors). The test consists of a series of 20 trials of a visual search and cancellation task. The respondent detects and marks through all occurrences of the two target digits: "2" and "7." In the 10 Automatic Detection trials, the target digits are embedded among alphabetical letters that serve as distractors. In the 10 Controlled Search trials, the target digits are embedded among other numbers that serve as distractors. Correct hits and errors are counted for each trial and serve as the basis for scoring the test. Speed scores reflect the total number of correctly identified targets (hits). Score range: 0 to 300, with higher numbers representing more correctly identified targets within the allotted time (5 minutes)'}, {'measure': 'Percent Change in Ruff 2 and 7 Controlled Search Accuracy Score', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Ruff 2 \\& 7 Test was developed to measure two aspects of visual attention: sustained attention (ability to maintain consistent performance level over time) and selective attention (ability to select relevant stimuli while ignoring distractors). The test consists of a series of 20 trials of a visual search and cancellation task. The respondent detects and marks through all occurrences of the two target digits: "2" and "7." In the 10 Automatic Detection trials, the target digits are embedded among alphabetical letters that serve as distractors. In the 10 Controlled Search trials, the target digits are embedded among other numbers that serve as distractors. Correct hits and errors are counted for each trial and serve as the basis for scoring the test. Accuracy scores evaluate the number of targets identified in relation to the number of possible targets (n=300), expressed as a percentage. Higher scores represent higher accuracy of target identification.'}, {'measure': 'Percent Change in Patient Health Questionnaire - 9 Scale Score.', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Participant Health Questionnaire 9 is a standardized assessment instrument designed to screen, diagnose, monitor, and measure the severity of depression. Score range: 0 to 27, lower scores correspond to better health outcomes.'}, {'measure': 'Number of Participants With ≥1 Point Increase in Glasgow Outcome Scale - Extended Scale Score', 'timeFrame': 'Pre-surgery baseline to treatment phase end (up to 197 days)', 'description': 'The Glasgow Outcome Scale Extended (GOS-E) is a measure of disability and handicap intended for use following head injury. The GOS-E subdivides the upper three categories of the original Glasgow Outcome Scale (GOS), severe disability, moderate disability and good recovery, into an eight-category scale: 1 = dead, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery to provide more detailed assessment of the functional effects of the injury. A structured interview has been developed to standardize assignment of an outcome category (Wilson et al. 1998). Increase of 1 point on this scale represents a meaningful change in health outcome.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'keywords': ['Deep brain stimulation', 'DBS', 'Central thalamus', 'TBI', 'Traumatic brain injury'], 'conditions': ['TBI (Traumatic Brain Injury)']}, 'referencesModule': {'references': [{'pmid': '9726257', 'type': 'BACKGROUND', 'citation': 'Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 1998 Aug;15(8):573-85. doi: 10.1089/neu.1998.15.573.'}, {'pmid': '38049620', 'type': 'DERIVED', 'citation': "Schiff ND, Giacino JT, Butson CR, Choi EY, Baker JL, O'Sullivan KP, Janson AP, Bergin M, Bronte-Stewart HM, Chua J, DeGeorge L, Dikmen S, Fogarty A, Gerber LM, Krel M, Maldonado J, Radovan M, Shah SA, Su J, Temkin N, Tourdias T, Victor JD, Waters A, Kolakowsky-Hayner SA, Fins JJ, Machado AG, Rutt BK, Henderson JM. Thalamic deep brain stimulation in traumatic brain injury: a phase 1, randomized feasibility study. Nat Med. 2023 Dec;29(12):3162-3174. doi: 10.1038/s41591-023-02638-4. Epub 2023 Dec 4."}]}, 'descriptionModule': {'briefSummary': 'This study involves the treatment of cognitive impairment secondary to moderate to severe brain injury using central thalamic deep brain stimulation. Although all patients will receive stimulation continuously through a surgically implanted pacemaker-like device, half of the patients will have the device deactivated during a blinded assessment phase. The device will be reactivated following this assessment and patients will have the option to continue stimulation in an open-label continuation.', 'detailedDescription': 'This preliminary safety study evaluates the use of the Medtronic Activa PC+S system and Medtronic Nexus-E system for central thalamic deep brain stimulation (CT-DBS) in the treatment of cognitive impairment secondary to traumatic brain injury (TBI). It involves a neurosurgical procedure in which electrodes are implanted in the brain, connected to an implanted pacemaker-like device in the chest. The proposed study, if successful, will provide supporting evidence for the development of a novel therapeutic approach utilizing CT-DBS to improve these enduring cognitive impairments arising in persons with multi-focal structural brain injuries. This research will address the critical gap of the lack of any available treatments. CT-DBS targets well-defined neuronal populations within the central thalamus that have known anatomical and physiological specializations, which not only provide a key role in arousal regulation during cognitively-mediated behaviors, but also exhibit a particular vulnerability to dysfunction in the setting of multi-focal, non-selective brain injuries.\n\nOur proposed study aims to support development of CT-DBS as a novel therapeutic avenue for accessing cognitive reserve in patients with acquired brain injuries. In the proposed feasibility study of 6 subjects at a single investigational site, we will test the safety of CT-DBS in the severe traumatic brain injury (STBI) population with GOSE 6-7 level recovery and collect data to establish the translation of preclinical studies into human application of CT-DBS.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '60 Years', 'minimumAge': '22 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* History of moderate to severe TBI based on worst GCS score within first 48 hours of injury (acceptable GCS range = 3-12)\n* Age 22-60\n* At least 24 months from date of onset\n* Fluent in English and able to independently provide consent\n* Rating of upper moderate disability to lower good recovery on the Glasgow Outcome Scale-Extended (GOSE) at time of enrollment (acceptable GOSE range 5-7)\n* Failure to return to pre-injury level of vocational or educational function\n* Either receiving no CNS stimulants or other medications known to affect cognitive function, or on stable doses of these medications for the last three months\n\nExclusion Criteria:\n\n* History of major developmental, neurologic, psychiatric or substance use disorder with evidence of disability prior to onset of TBI\n* Major medical co-morbidities including: end stage renal failure, severe heart failure, coagulopathy, severe respiratory problems, severe liver failure, uncontrolled hypertension or other significant medical co morbidities\n* Have had a documented seizure within 3 months of study screening (subjects may re-screen if seizure free after initial screen failure)\n* Malignancy with \\< 5 years life expectancy\n* Untreated / uncontrolled (severe at the time of enrollment) depression or other psychiatric disorder\n* Women of childbearing age who do not regularly use an accepted contraceptive method\n* Inability to stop anticoagulation therapy or platelet anti-aggregation therapy before, during and after surgery\n* Previous DBS or other brain implants\n* Previous ablative intracranial surgery\n* Implantable hardware not compatible with MRI\n* Condition requiring diathermy after DBS implantation\n* Hardware, lesions or other factors limiting placement of electrodes in optimal target location in the judgment of the operating surgeon\n* Concurrent enrollment in any other clinical trial\n* Any condition or finding that, in the judgment of the PI, significantly increases risk or significantly reduces the likelihood of benefit from DBS'}, 'identificationModule': {'nctId': 'NCT02881151', 'briefTitle': 'Deep Brain Stimulation for the Treatment of Traumatic Brain Injury', 'organization': {'class': 'OTHER', 'fullName': 'Stanford University'}, 'officialTitle': 'CT-DBS for Traumatic Brain Injury Using the Medtronic Activa PC+S System', 'orgStudyIdInfo': {'id': '37280'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Treatment', 'description': 'Subjects will be treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that will be undertaken to assess for any possible therapeutic effect.', 'interventionNames': ['Device: Deep brain stimulation']}], 'interventions': [{'name': 'Deep brain stimulation', 'type': 'DEVICE', 'otherNames': ['DBS', 'CT-DBS', 'Central Thalamic DBS'], 'description': 'Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.', 'armGroupLabels': ['Treatment']}]}, 'contactsLocationsModule': {'locations': [{'zip': '94305', 'city': 'Stanford', 'state': 'California', 'country': 'United States', 'facility': 'Stanford Health Care', 'geoPoint': {'lat': 37.42411, 'lon': -122.16608}}], 'overallOfficials': [{'name': 'Jaimie M Henderson, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Stanford University'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Jaimie M. Henderson', 'class': 'OTHER'}, 'collaborators': [{'name': 'Weill Medical College of Cornell University', 'class': 'OTHER'}, {'name': 'University of Utah', 'class': 'OTHER'}, {'name': 'Harvard Medical School (HMS and HSDM)', 'class': 'OTHER'}, {'name': 'The Cleveland Clinic', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'John and Jene Blume - Robert and Ruth Halperin Professor', 'investigatorFullName': 'Jaimie M. Henderson', 'investigatorAffiliation': 'Stanford University'}}}}